Premium
Methods to Identify Immunogenic Peptides in SARS‐CoV‐2 Spike and Protective Monoclonal Antibodies in COVID‐19 Patients
Author(s) -
Li Lili,
Gao Meiling,
Li Jie,
Zu Shulong,
Wang Yanan,
Chen Chunfeng,
Wan Dingyi,
Duan Jing,
Aliyari Roghiyh,
Wang Jingfeng,
Zhang Jicai,
Jin Yujie,
Huang Weijin,
Jin Xiaoxia,
Shi Minxin,
Wang Youchun,
Qin ChengFeng,
Yang Heng,
Cheng Genhong
Publication year - 2021
Publication title -
small methods
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.66
H-Index - 46
ISSN - 2366-9608
DOI - 10.1002/smtd.202100058
Subject(s) - monoclonal antibody , epitope , antibody , virology , covid-19 , coronavirus , immunology , immune system , biology , medicine , infectious disease (medical specialty) , disease , pathology
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and the associated COVID‐19 diseases are an emerging threat to global public health. Although considerable scientific research on the immune, especially antibody, responses to SARS‐CoV‐2 infection have been conducted, additional dominant epitopes and protective antibodies are needed for diagnosis and treatment of COVID‐19 patients. Here, two different phage libraries are used to identify immunogenic epitopes across the spike protein and monoclonal antibodies from COVID‐19 patients. Three peptides are further characterized in the receptor‐binding motif (RBM) and measured their antibody levels in COVID‐19 patients, from which one identifies one most immunodominant epitope with the highest antibody response in COVID‐19 patients and in immunized mice. More importantly, monoclonal antibodies specifically binding to this peptide isolated from COVID‐19 patients have therapeutic potential to neutralize SARS‐CoV‐2 infection. Thus, the approaches to systemically identify immunogenic peptides and directly identify human monoclonal antibodies from patients will provide useful diagnostic and therapeutic tools for COVID‐19 and other emerging infectious diseases.